Ranked #853 of 8,699 institutional investors
Orbimed Advisors LLC
New York, NY
$4.74B
US stock portfolio at live prices · today +$18.6M (+0.39%)
Market closed. Prices as of Nov 20, 6:41 AM ET
- Value at quarter end (Q3 2026)
- $5.26B
- Change from Q2 2026
- +$164.5M (+3.23%)
- Positions
- 105 · 27 new, 27 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $44.4M of stock, put options on $1.2M, $10.5M of convertible notes and other principal-amount securities. $308M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesEWTX 13.5%LLY 7.35%ADRX 7.23%ELVN 6.63%BRVE 4.95%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| EWTX Edgewise Therapeutics, Inc. | 15,518,492 | $639M | 13.5% | Unchanged |
| LLY Eli Lilly and Company | 257,900 | $348M | 7.35% | Unchanged |
| ADRX ADARx Pharmaceuticals, Inc. | 24,205,789 | $343M | 7.23% | New |
| ELVN Enliven Therapeutics, Inc. | 6,776,632 | $315M | 6.63% | Unchanged |
| BRVE Braveheart Bio, Inc. | 12,175,159 | $235M | 4.95% | New |
| MBX MBX Biosciences, Inc. | 3,074,853 | $164M | 3.46% | Reduced −10% |
| MRK Merck & Co., Inc. | 946,100 | $126M | 2.65% | Added +43% |
| EW Edwards Lifesciences Corporation | 834,900 | $86.7M | 1.83% | Unchanged |
| GH Guardant Health, Inc. | 584,100 | $85.0M | 1.79% | Unchanged |
| ARQT Arcutis Biotherapeutics, Inc. | 3,122,100 | $84.8M | 1.79% | Added +53% |
| TMO Thermo Fisher Scientific Inc. | 120,400 | $82.9M | 1.75% | Added +33% |
| ABBV AbbVie Inc. | 259,600 | $73.6M | 1.55% | New |
| UNH UnitedHealth Group Incorporated | 219,000 | $72.4M | 1.53% | Added +36% |
| CRVS Corvus Pharmaceuticals, Inc. | 7,165,006 | $71.7M | 1.51% | Unchanged |
| ARGX argenx SE | 75,180 | $70.8M | 1.49% | Reduced −19% |
| CDNA CareDx, Inc. | 934,800 | $67.2M | 1.42% | New |
| TNGX Tango Therapeutics, Inc. | 2,777,621 | $63.1M | 1.33% | New |
| PRAX Praxis Precision Medicines, Inc. | 200,400 | $62.3M | 1.31% | Reduced −13% |
| ETRA Electra Therapeutics, Inc. | 6,885,170 | $61.6M | 1.30% | New |
| ABT Abbott Laboratories | 579,000 | $60.1M | 1.27% | New |
| TVTX Travere Therapeutics, Inc. | 1,200,425 | $58.0M | 1.22% | Added +374% |
| NTRA Natera, Inc. | 199,700 | $57.9M | 1.22% | Reduced −24% |
| COGT Cogent Biosciences, Inc. | 2,003,700 | $55.6M | 1.17% | Added +19% |
| ODTX Odyssey Therapeutics, Inc. | 3,001,198 | $55.0M | 1.16% | Unchanged |
| HUM Humana Inc. | 127,800 | $48.6M | 1.02% | Reduced −22% |
| RYTM Rhythm Pharmaceuticals, Inc. | 408,000 | $47.7M | 1.00% | Added +26% |
| PRLD Prelude Therapeutics Incorporated | 13,724,571 | $44.7M | 0.94% | Unchanged |
| CAI Caris Life Sciences, Inc. | 2,192,911 | $40.7M | 0.86% | Reduced −22% |
| ISRG Intuitive Surgical, Inc. | 96,800 | $39.4M | 0.83% | Reduced −39% |
| BLSM BlossomHill Therapeutics, Inc. | 2,714,279 | $39.1M | 0.82% | New |
| QTTB Q32 Bio Inc. | 4,127,987 | $35.0M | 0.74% | Unchanged |
| AVBP ArriVent BioPharma, Inc. | 3,027,328 | $34.1M | 0.72% | Unchanged |
| PVLA Palvella Therapeutics, Inc. | 229,860 | $33.5M | 0.71% | Reduced −21% |
| WST West Pharmaceutical Services, Inc. | 80,180 | $31.8M | 0.67% | Added +14% |
| KRYS Krystal Biotech, Inc. | 97,700 | $30.9M | 0.65% | Added +17% |
| STTK Shattuck Labs, Inc. | 6,306,127 | $28.7M | 0.61% | Unchanged |
| SPRY ARS Pharmaceuticals, Inc. | 8,288,510 | $27.8M | 0.59% | Unchanged |
| AURA Aura Biosciences, Inc. | 3,333,333 | $23.3M | 0.49% | Unchanged |
| AXSM Axsome Therapeutics, Inc. | 170,878 | $23.2M | 0.49% | Added +45% |
| GPCR Structure Therapeutics Inc. | 1,331,000 | $22.8M | 0.48% | Reduced −40% |
| DXCM DexCom, Inc. | 278,000 | $22.3M | 0.47% | New |
| LTGO Latigo Biotherapeutics, Inc. | 1,675,316 | $22.2M | 0.47% | New |
| SVRA Savara Inc. | 3,959,900 | $20.6M | 0.44% | Unchanged |
| MLYS Mineralys Therapeutics, Inc. | 1,454,572 | $20.6M | 0.43% | Reduced −31% |
| BIIB Biogen Inc. | 79,400 | $19.6M | 0.41% | Added +29% |
| WAT Waters Corporation | 40,300 | $18.4M | 0.39% | Unchanged |
| SCTX Scribe Therapeutics Inc. | 1,348,825 | $17.8M | 0.38% | New |
| CELC Celcuity Inc. | 314,500 | $17.7M | 0.37% | New |
| APMD Apnimed, Inc. | 925,000 | $16.0M | 0.34% | New |
| ABVX ABIVAX Société Anonyme | 185,022 | $14.9M | 0.31% | Reduced −66% |
| CVS CVS Health Corporation | 182,600 | $14.6M | 0.31% | New |
| CLDX Celldex Therapeutics, Inc. | 505,000 | $14.1M | 0.30% | New |
| PYXS Pyxis Oncology, Inc. | 8,361,917 | $14.0M | 0.30% | New |
| QUIT Achieve Life Sciences, Inc. | 2,344,200 | $13.8M | 0.29% | New |
| VRTX Vertex Pharmaceuticals Incorporated | 26,200 | $13.6M | 0.29% | New |
| TRVI Trevi Therapeutics, Inc. | 965,300 | $13.2M | 0.28% | Reduced −33% |
| DFTX Definium Therapeutics, Inc. | 443,900 | $13.1M | 0.28% | Added +21% |
| NKTR Nektar Therapeutics | 384,520 | $12.5M | 0.26% | Reduced −17% |
| VOGX Vogenx, Inc. | 968,621 | $12.4M | 0.26% | New |
| WHWK Whitehawk Therapeutics, Inc. | 3,853,472 | $12.0M | 0.25% | Reduced −2% |
| ORIC ORIC Pharmaceuticals, Inc. | 1,555,900 | $12.0M | 0.25% | Reduced −23% |
| ERAS Erasca, Inc. | 806,000 | $11.5M | 0.24% | Added +63% |
| UPB Upstream Bio, Inc. | 5,693,589 | $11.4M | 0.24% | Unchanged |
| RVMD Revolution Medicines, Inc. | 70,500 | $11.2M | 0.24% | Unchanged |
| BCRX BioCryst Pharmaceuticals, Inc. | 1,506,000 | $11.0M | 0.23% | Reduced −19% |
| CMPX Compass Therapeutics, Inc. | 15,219,994 | $10.3M | 0.22% | Unchanged |
| SPRB Spruce Biosciences, Inc. | 242,800 | $9.8M | 0.21% | Added +21% |
| LXEO Lexeo Therapeutics, Inc. | 3,203,050 | $9.4M | 0.20% | Reduced −19% |
| KROS Keros Therapeutics, Inc. | 759,155 | $8.6M | 0.18% | Unchanged |
| NPCE NeuroPace, Inc. | 1,055,125 | $8.6M | 0.18% | Reduced −30% |
| ARWR Arrowhead Pharmaceuticals, Inc. | 194,300 | $8.5M | 0.18% | New |
| TSHA Taysha Gene Therapies, Inc. | 2,000,000 | $7.5M | 0.16% | Unchanged |
| SION Sionna Therapeutics, Inc. | 2,469,959 | $7.3M | 0.15% | Reduced −3% |
| STRO Sutro Biopharma, Inc. | 743,944 | $6.5M | 0.14% | Unchanged |
| JANX Janux Therapeutics, Inc. | 524,700 | $5.4M | 0.11% | Unchanged |
| RLMD Relmada Therapeutics, Inc. | 1,670,079 | $5.2M | 0.11% | Reduced −54% |
| SYRE Spyre Therapeutics, Inc. | 47,326 | $4.6M | <0.1% | Reduced −75% |
| XLO Xilio Therapeutics, Inc. | 592,300 | $4.4M | <0.1% | Unchanged |
| DHR Danaher Corporation | 18,600 | $4.2M | <0.1% | New |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 1,665,656 | $4.1M | <0.1% | Reduced −4% |
| YARW Yarrow Bioscience, Inc. | 266,306 | $3.8M | <0.1% | New |
| IMA ImageneBio, Inc. | 909,269 | $3.6M | <0.1% | Unchanged |
| DNTH Dianthus Therapeutics, Inc. | 42,300 | $3.6M | <0.1% | Reduced −63% |
| IMUX Immunic, Inc. | 475,804 | $3.5M | <0.1% | New |
| TECX Tectonic Therapeutic, Inc. | 166,102 | $3.5M | <0.1% | Reduced −27% |
| BIOA BioAge Labs, Inc. | 711,811 | $3.4M | <0.1% | Reduced −5% |
| BMRN BioMarin Pharmaceutical Inc. | 54,300 | $3.3M | <0.1% | New |
| AORT Artivion, Inc. | 175,000 | $3.2M | <0.1% | Unchanged |
| MDGL Madrigal Pharmaceuticals, Inc. | 8,000 | $3.2M | <0.1% | New |
| BRKR Bruker Corporation | 48,400 | $3.0M | <0.1% | New |
| PTCT PTC Therapeutics, Inc. | 49,100 | $2.9M | <0.1% | Unchanged |
| ALXO ALX Oncology Holdings Inc. | 2,742,968 | $2.8M | <0.1% | Reduced −4% |
| TARS Tarsus Pharmaceuticals, Inc. | 34,600 | $2.7M | <0.1% | Reduced −3% |
| ALMS Alumis Inc. | 548,163 | $2.4M | <0.1% | Unchanged |
| ACET Adicet Bio, Inc. | 844,787 | $2.1M | <0.1% | Unchanged |
| BLTE Belite Bio, Inc | 13,300 | $2.0M | <0.1% | Unchanged |
| NSPR InspireMD, Inc. | 3,133,405 | $1.9M | <0.1% | Unchanged |
| ZNTL Zentalis Pharmaceuticals, Inc. | 1,315,355 | $1.8M | <0.1% | Reduced −5% |
| DRUG Bright Minds Biosciences Inc. | 81,000 | $1.7M | <0.1% | Reduced −13% |
| UNCY Unicycive Therapeutics, Inc. | 387,000 | $1.4M | <0.1% | New |
| OCUL Ocular Therapeutix, Inc. | 220,000 | $1.3M | <0.1% | Unchanged |
| EPRX Eupraxia Pharmaceuticals Inc. | 194,720 | $1.2M | <0.1% | Reduced −28% |
| EVMN Evommune Inc | 161,000 | $1.2M | <0.1% | Unchanged |
| TRAW Traws Pharma, Inc. | 1,203,260 | $277K | <0.1% | Unchanged |
| EYPT EyePoint, Inc. | 739,691 | $195K | <0.1% | Reduced −31% |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| CGON CG Oncology, Inc. | 972,800 | $79.7M |
| BSX Boston Scientific Corporation | 1,483,200 | $63.8M |
| BMY Bristol-Myers Squibb Company | 925,000 | $54.0M |
| DYN Dyne Therapeutics, Inc. | 3,235,684 | $51.9M |
| SYK Stryker Corporation | 159,100 | $49.8M |
| ELV Elevance Health, Inc. | 114,700 | $44.8M |
| XENE Xenon Pharmaceuticals Inc. | 892,471 | $33.5M |
| IRON Disc Medicine, Inc. | 357,535 | $27.2M |
| SNDX Syndax Pharmaceuticals, Inc. | 1,542,000 | $14.1M |
| LFST LifeStance Health Group, Inc. | 947,400 | $12.6M |
| MNPR Monopar Therapeutics Inc. | 157,423 | $11.1M |
| VERA Vera Therapeutics, Inc. | 369,596 | $9.9M |
| ANRO Alto Neuroscience Inc | 257,852 | $6.8M |
| TARA Protara Therapeutics, Inc. | 2,220,000 | $5.3M |
| PTGX Protagonist Therapeutics, Inc. | 42,100 | $5.2M |
| AMLX Amylyx Pharmaceuticals, Inc. | 183,400 | $4.8M |
| ALNY Alnylam Pharmaceuticals, Inc. | 17,000 | $2.5M |
| ACAD Acadia Pharmaceuticals Inc. | 137,000 | $2.4M |
| PALI Palisade Bio, Inc. | 2,333,000 | $2.2M |
| TYRA Tyra Biosciences, Inc. | 102,000 | $2.0M |
| RAPP Rapport Therapeutics, Inc. | 76,616 | $1.8M |
| OVID Ovid Therapeutics Inc. | 747,000 | $1.7M |
| BCAX Bicara Therapeutics Inc. | 191,100 | $1.7M |
| ACRS Aclaris Therapeutics, Inc. | 421,500 | $1.5M |
| CYTK Cytokinetics, Incorporated | 25,800 | $1.3M |
| AGMB AgomAb Therapeutics NV | 192,740 | $1.1M |
| NMRA Neumora Therapeutics, Inc. | 2,139,882 | $743K |